Pfizer, BioNTech start consolidated preliminaries of COVID-19 immunization candidate in Japan
- Post By : Kumar Jeetendra
- Source: Reuters
- Date: 20 Oct,2020
Pfizer Inc and BioNTech SE announced on Tuesday the start in Japan of combined Phase I and Phase II clinical trials of the mRNA vaccine candidate against the coronavirus.
Earlier, they had agreed to supply Japan with 120 million doses of their experimental coronavirus vaccine in the first half of 2021.
Pfizer, which is developing the vaccine with German spouse BioNTech, has said it may confirm whether the vaccine is effective as soon as this month, but also needs safety data from a global trial of 44,000 people which won’t be available until next month.
Japan has pledged to secure enough vaccine supply for its whole population from the middle of 2021.
Clinical trials of AstraZeneca and Oxford University’s experimental COVID-19 vaccine declared in Japan this month after being placed on hold over the illness of a British volunteer.